CTOs on the Move

Seraxis

www.seraxis.com

 
Seraxis is a privately owned biotechnology company. Our GMP lab is located in Germantown, Maryland, in the heart of the vibrant BioHealth Capital Region. Launched in early 2013, Seraxis used proprietary technologies to develop a cell replacement therapy, SR-01, that is more effective and safer than embryonic stem cell-derived therapies.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.seraxis.com
  • 20271 Goldenrod Lane #2085
    Germantown, MD USA 20876
  • Phone: N/A

Executives

Name Title Contact Details

Funding

Seraxis raised $40M on 02/09/2021

Similar Companies

Ignyta

Ignyta, located in San Diego, California, is a biotechnology company developing precision medicine with integrated Rx/Dx solutions for cancer patients. Its goal is to discover and develop revolutionary new drugs that target activated genes in cancer cells for the customized treatment of cancer patients. The company's present focus is on the development of RXDX-101, its proprietary oral tyrosine kinase inhibitor that targets solid tumor indications, and advancing its novel Spark discovery programs that leverage its proprietary cancer genomic and epigenomic knowledge bases

BioStar Systems

BioStar Systems is a Kansas City, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Soliance

Soliance is a Allendale, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Boston BioCom

Boston BioCom is a Boston, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Federation Bio

Federation Bio is a biotechnology company pioneering a novel approach to create potent, durable and safe cell therapies. The company`s first-in-class platform combines the power of genetic engineering and synthetic consortium design to control systemic immune responses and broad metabolic functions. Federation Bio`s pipeline addresses a range of serious illnesses from metabolic disorders to metastatic cancer. The company`s lead program is in enteric hyperoxaluria, a serious renal condition that affects more than 250,000 Americans and for which there are currently no approved therapies.